Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Appoints Former Rhone-Poulenc CEO Thurman, to Board

Premium

N

EW HAVEN, Conn.--CuraGen announced that Randy Thurman, past president and CEO of Rhone-Poulenc Rorer Pharmaceuticals, has joined its board of directors. "Over the last 18 months, CuraGen has made tremendous progress forward-integrating into a genomics-based biopharmaceutical company. Joining CuraGen’s board provides me with an opportunity to utilize my experience in the pharmaceutical and life science industries in providing strategic guidance as CuraGen develops a proprietary product pipeline," said Thurman, who is now chairman and CEO of Strategic Reserves International, a company he founded to provide direction to emerging health care technology companies.

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.